-- Management to Host Conference Call at 4:30
p.m. ET Today --
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of patients with cancer and autoimmune diseases, today
reported financial results for the first quarter ended March 31,
2023 and provided a review of recent business and clinical
highlights.
“In the first quarter, we and our partners continued to enroll
patients across multiple Phase 1 and Phase 2 clinical studies of
XmAb drug candidates in oncology and autoimmune diseases. Two new
programs are planned to advance into clinical development this
year, XmAb662, our engineered IL12-Fc cytokine, on track to start a
Phase 1 study mid-year, and XmAb541, our CLDN6 x CD3 bispecific
antibody for ovarian cancer, for which we anticipate submitting the
IND by year end,” said Bassil Dahiyat, Ph.D., president and chief
executive officer at Xencor. “And recently, we added to our team
the expertise and talents of Nancy Valente, M.D., who will lead our
clinical programs as our new executive vice president and chief
development officer.”
Program and Corporate Updates
- XmAb564 (IL2-Fc): The Company will present updated
results from the Phase 1a single-ascending dose study in healthy
volunteers at European Alliance of Associations for Rheumatology
(EULAR) Congress, being held from May 31 to June 1, in Milan,
Italy. The update will include additional biomarker data. Data
previously presented demonstrate a single dose, administered
subcutaneously in healthy volunteers, was well tolerated and
generated durable, dose-dependent and selective expansion of
regulatory T cells.
- XmAb104 (PD-1 x ICOS): XmAb104 is a bispecific antibody
that targets PD-1, an immune checkpoint receptor, and ICOS, an
immune co-stimulatory receptor, to selectively activate the tumor
microenvironment. Initial dose-escalation data from a Phase 1
study, presented at ASCO 2022, indicates that XmAb104 was well
tolerated and exhibited a distinct safety profile compared to other
clinical-stage ICOS programs. Anti-tumor activity was observed in
patients, and biomarker activity was consistent with engagement
with T cells. The Company has opened an expansion portion in the
study (Part C) to evaluate XmAb104 in combination with ipilimumab
in patients with microsatellite stable or proficient mismatch
repair colorectal cancer.
- Preclinical Data Presentation: Preclinical data
generated from engineered CD28 bispecific antibodies targeting the
solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2
were presented at the American Association for Cancer Research
(AACR) Annual Meeting in April 2023.
- Corporate Update: Nancy Valente, M.D., was appointed as
Xencor’s Executive Vice President, Chief Development Officer,
effective May 1, having previously served as an independent member
of the Company’s Board of Directors from September 2022 through
April 2023. Dr. Valente brings with her more than 20 years of
experience in late-stage biopharmaceutical product development. She
most recently served as a senior vice president at Genentech, a
member of the Roche Group, and as its global head and co-lead of
global product development of its oncology and hematology
therapeutic area.
Progress Across Partnered Programs
- Alexion Pharmaceuticals, Inc.: In April 2023, Ultomiris®
(ravulizumab-cwvz), which incorporates Xencor’s Xtend™ Fc domain,
was recommended for marketing authorization in the EU for the
treatment of adult patients with neuromyelitis optica spectrum
disorder (NMOSD) who are anti-aquaporin-4 antibody positive. In
addition, AstraZeneca recently announced that a Phase 3 study of
Ultomiris has been initiated in cardiac surgery-associated acute
kidney injury. In the first quarter of 2023, Xencor earned $10.5
million of royalty revenue from Alexion on net sales of
Ultomiris.
Ultomiris is a registered trademark of Alexion Pharmaceuticals,
Inc.
Financial Results for the First Quarter Ended March 31,
2023
Cash, cash equivalents, receivables and marketable debt
securities totaled $568.2 million as of March 31, 2023, compared to
$613.5 million on December 31, 2022.
Revenues for the first quarter ended March 31, 2023 were $19.0
million, compared to $85.5 million for the same period in 2022.
Total revenues earned in the first quarter of 2023 included
milestone revenue earned from Xencor’s Janssen collaboration and
royalties from the Alexion agreement, compared to revenue earned
from the Janssen collaboration, milestone revenue from Astellas,
and royalties from the Alexion, MorphoSys and Vir agreements in the
first quarter of 2022.
Research and development expenses for the first quarter ended
March 31, 2023 were $64.4 million, compared to $47.8 million for
the same period in 2022. Increased research and development
spending for first quarter of 2023 compared to 2022 reflects
increased spending on the Company’s development programs including
XmAb541 and XmAb564 and other research and early-stage
programs.
General and administrative expenses for the first quarter ended
March 31, 2023 were $14.0 million, compared to $11.3 million in the
same period in 2022. Increased general and administrative spending
for the first quarter of 2023 compared to 2022 reflects increased
facility expenses and additional spending on professional fees.
Non-cash, stock-based compensation expense for the first quarter
ended March 31, 2023 was $12.6 million, compared to $10.8 million
for the same period in 2022.
Net loss for the first quarter ended March 31, 2023 was $60.8
million, or $(1.02) on a fully diluted per share basis, compared to
a net income of $23.6 million, or $0.39 on a fully diluted per
share basis, for the same period in 2022. Net loss reported for the
first quarter of 2023 compared to net income for the same period in
2022 is primarily due to decreased royalties from the Vir
agreement.
The total shares outstanding were 60,381,600 as of March 31,
2023, compared to 59,529,192 as of March 31, 2022.
Financial Guidance
Based on current operating plans, Xencor expects to have cash to
fund research and development programs and operations through the
end of 2025. The Company expects to end 2023 with between $425
million and $475 million in cash, cash equivalents, receivables and
marketable debt securities.
Conference Call and Webcast
Xencor will host a conference call today at 4:30 p.m. ET (1:30
p.m. PT) to discuss the first quarter 2023 financial results and
provide a corporate update.
The live webcast will be available under “Events &
Presentations” in the Investors section of the Company’s website
located at investors.xencor.com and will be archived for at least
30 days. Active participants in the conference call may receive
credentials for telephone access by registering at the following
link:
https://register.vevent.com/register/BI0da076297f5f4f3b920845d8b0e7f2d3.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
“potential,” “can,” “will,” “plan,” “may,” “could,” “would,”
“expect,” “anticipate,” “seek,” “look forward,” “believe,”
“committed,” “investigational,” and similar terms, or by express or
implied discussions relating to Xencor’s business, including, but
not limited to, statements regarding planned additional clinical
trials, the quotations from Xencor's president and chief executive
officer, our projected financial resources and other statements
that are not purely statements of historical fact. Such statements
are made on the basis of the current beliefs, expectations, and
assumptions of the management of Xencor and are subject to
significant known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements
and the timing of events to be materially different from those
implied by such statements, and therefore these statements should
not be read as guarantees of future performance or results. Such
risks include, without limitation, the risks associated with the
process of discovering, developing, manufacturing and
commercializing drugs that are safe and effective for use as human
therapeutics and other risks, including the ability of publicly
disclosed preliminary clinical trial data to support continued
clinical development and regulatory approval for specific
treatments, in each case as described in Xencor's public securities
filings. For a discussion of these and other factors, please refer
to Xencor's annual report on Form 10-K for the year ended December
31, 2022 as well as Xencor's subsequent filings with the Securities
and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
as amended to date. All forward-looking statements are qualified in
their entirety by this cautionary statement and Xencor undertakes
no obligation to revise or update this press release to reflect
events or circumstances after the date hereof, except as required
by law.
Xencor, Inc. Condensed Balance Sheets (in
thousands) March 31, December 31,
2023
2022
(unaudited) Assets Current assets Cash and
cash equivalents
$
72,394
$
53,942
Marketable debt securities
475,922
526,689
Marketable equity securities
39,706
42,431
Accounts receivable
19,861
28,997
Prepaid expenses
22,093
23,283
Total current assets
629,976
675,342
Property and equipment, net
66,685
59,183
Intangible assets, net
18,244
18,500
Marketable debt securities - long term
—
3,826
Marketable equity securities - long term
54,210
54,383
Right of use asset
33,697
34,419
Other assets
599
613
Total assets
$
803,411
$
846,266
Liabilities and stockholders’ equity Current
liabilities Accounts payable and accrued liabilities
$
30,481
$
28,816
Deferred revenue
30,104
30,320
Lease liabilities
4,471
4,708
Total current liabilities
65,056
63,844
Lease liabilities, net of current portion
54,772
54,926
Total liabilities
119,828
118,770
Stockholders’ equity
683,583
727,496
Total liabilities and stockholders’ equity
$
803,411
$
846,266
The 2022 balance sheet was derived from the 2022 annual
financial statements included in the Form 10-K that was filed on
February 24, 2023 Xencor Inc. Condensed
Statements of Comprehensive Income (Loss) (in thousands,
except share and per share data) Three months ended
March 31,
2023
2022
(unaudited)
Revenues $
18,962
$
85,495
Operating expenses: Research and development
64,379
47,756
General and administrative
13,948
11,273
Total operating expenses
78,327
59,029
Income (loss) from operations
(59,365
)
26,466
Other expense, net
(1,398
)
(2,872
)
Net income (loss)
(60,763
)
23,594
Other comprehensive gain (loss) Net unrealized gain (loss)
on marketable debt securities
3,327
(5,611
)
Comprehensive income (loss) $
(57,436
)
$
17,983
Net income (loss) per share: Basic net
income (loss) per share $
(1.02
)
$
0.40
Diluted net income (loss) per share $
(1.02
)
$
0.39
Weighted-average number of common shares used in net income
(loss) per share applicable to common stockholders - basic
59,771,674
59,407,829
Weighted-average number of common shares used in net income
(loss) per share applicable to common stockholders - diluted
59,771,674
61,078,494
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230508005616/en/
For Investors: Charles Liles cliles@xencor.com (626)
737-8118
For Media: Jason I. Spark Evoke Canale
jason.spark@evokegroup.com (619) 849-6005
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2023 to Mar 2024